Abstract
ALK gene rearrangement accounts for approximately 5%-7% in non-small cell lung cancer (NSCLC), and usually demonstrate a response to ALK tyrosine kinase inhibitors (TKIs). However, a recent study showed that the presence of nonreciprocal/reciprocal ALK translocation was predictive for shorter PFS and greater risk of brain metastases (BM) in patients with ALK-rearranged NSCLC. Herein, we report that, for the first time, one NSCLC patient with the coexistence of a novel NBAS-ALK, EML4-ALK double-fusion responds to ensartinib after disease progression on sequential crizotinib, alectinib, ceritinib, and then chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
